Report: Polypid To Delay Offering Until 2015

December 1, 2014 | Despite recent announcements that the biomedical company Polypid would seek to raise $20 million at a company valuation of $100 million on NASDAQ, the company is likely to put off the offering until the beginning of 2015. The comment was made by Haim Horowitz, the head of the cHealth innovation fund, to “Globes,” with Horowitz stating that the company decided to put off the IPO due to weak markets in anticipation of the holiday season. The offering was set to be led by underwriters Aegis and secondary underwriters Chardan Capital and MLV. Polypid is best known for the development of extended-release tablets against bone fracture infections.